摘要
目的探讨B及T淋巴细胞弱化因子(BTLA)、细胞毒性T淋巴细胞抗原-4(CTLA-4)基因多态性与肝癌经动脉插管化疗栓塞(TACE)联合靶向治疗疗效及预后相关性。方法选取2021年1月至2021年12月期间南通大学附属医院介入放射科收治的新发85例肝癌患者作为研究对象,均行TACE联合靶向治疗,根据RECIST实体瘤疗效评价标准将患者分为治疗有效组(n=58)、疾病进展组(n=27),比较2组临床资料、BTLA、CTLA-4基因多态性,分析BTLA、CTLA-4基因多态性与疗效的相关性,并于治疗后18个月电话随访生存状况,对比不同基因型患者生存状况,分析其与生存预后的相关性。结果CTLA-4 rs231775、rs733618、rs3087243、rs4553808位点、BTLA rs2171513、rs3112270、rs1982809、rs16859629位点基因型均符合HardyWeinberg遗传平衡定律;治疗有效组BTLA rs3112270位点AG、GG基因型比例、rs1982809位点GA、AA比例、rs16859629位点CC基因型、CTLA-4 rs231775位点AA基因型比例、rs3087243位点GA、AA基因型低于疾病进展组,BTLA rs3112270位点AA基因型比例、rs1982809位点GG比例、rs16859629位点TT基因型、CTLA-4 rs231775位点GG基因型比例、rs3087243位点GG基因型高于疾病进展组(P<0.05);单因素、多因素分析显示,BTLA rs3112270 A>G、rs1982809 G>A、rs16859629 T>C、CTLA-4 rs231775 A>G、rs3087243 G>A与疗效相关(P<0.05);BTLA rs3112270位点AA、AG基因型患者18个月生存率高于GG基因型患者,rs1982809位点GG、GA基因型患者18个月生存率高于AA基因型患者,rs16859629位点TT基因型患者18个月生存率高于TC、CC基因型患者(P<0.05);CTLA-4 rs231775位点GG、GA基因型患者18个月生存率高于AA基因型患者、rs3087243位点GG基因型18个月生存率高于GA、AA基因型患者(P<0.05);单因素、多因素分析显示,BTLA rs3112270 A>G、rs1982809 G>A、rs16859629 T>C、CTLA-4 rs231775 A>G、rs3087243G>A与生存预后相关(P<0.05)。结论BTLA基因rs3112270、rs1982809、rs16859629、CTLA-4基因rs231775、rs3087243位点多态性与肝癌TACE联合靶向治疗疗效、预后密切相关,以期为预估TACE治疗提供参考。
Objective To investigate the correlation between gene polymorphisms of B and T lymphocyte attenuator(BTLA)and cytotoxic T lymphocyte antigen-4(CTLA-4)and the efficacy and prognosis of targeted therapy combined with transcatheter arterial chemoembolization(TACE)for liver cancer.Methods Eighty-five new hepatocellular carcinoma patients admitted to the Department of Interventional Radiology of Nantong University Hospital between 2021-01-01 and 2021-12-31 were selected for the study,and all of them were treated with TACE combined with targeted therapy.According to the RECIST solid tumor efficacy evaluation criteria,the patients were divided into the effective treatment group(n=58)and the disease progression group(n=27).The clinical data,BTLA,CTLA-4 gene polymorphisms between the 2 groups were compared and the correlation between BTLA,CTLA-4 gene polymorphisms and efficacy were analyzed,And follow-up survival status by phone at 18 months after the treatment was conducted to compare the survival status of patients with different genotypes,and analyze their correlation with survival prognosis.Results CTLA-4 rs231775,rs733618,rs3087243,rs4553808,BTLA and the genotypes of rs2171513,rs3112270,rs1982809 and rs16859629 all conformed to Hardy-Weinberg law of genetic balance.The BTLA rs3112270 AG,GG genotype ratio,rs1982809 GA,AA ratio,rs16859629 CC genotype,CTLA-4 rs231775 AA genotype ratio,rs3087243 GA,AA genotype ratio in the treatment effective group were all lower than those in the disease progression group,while the proportion of AA genotype at BTLA rs3112270,GG genotype at rs1982809,TT genotype at rs16859629,GG genotype at CTLA-4 rs231775,and GG genotype at rs3087243 were all higher than those in the disease progression group(P<0.05);Univariate and multivariate analysis showed that BTLA rs3112270 A>G,rs1982809 G>A,rs16859629 T>C,CTLA-4 rs231775 A>G,rs3087243 G>A were all associated with the efficacy(P<0.05);The 18 month survival rate of BTLA rs3112270 AA and AG genotype patients was higher than that of GG genotype patients,rs1982809 GG and GA genotype patients were higher than that of AA genotype patients,and rs16859629 TT genotype patients are higher than those of TC and CC genotype patients(P<0.05);The 18 month survival rate of patients with CTLA-4 rs231775 GG and GA genotypes was higher than that of patients with AA genotypes,and the 18 month survival rate of GG genotype at rs3087243 was higher than that of patients with GA and AA genotypes(P<0.05);Univariate and multivariate analysis showed that BTLA rs3112270 A>G,rs1982809 G>A,rs16859629 T>C,CTLA-4 rs231775 A>G,rs3087243 G>A were all associated with the survival prognosis(P<0.05).Conclusion The polymorphisms of BTLA gene rs3112270,rs1982809,rs16859629,CTLA-4 gene rs231775,rs3087243 are closely related to the efficacy and prognosis of TACE combined with the targeted therapy for liver cancer and these will provide the reference for predicting TACE treatment.
作者
陆小华
袁洪新
LU Xiaohua;YUAN Hongxin(Dept.of Interventional Radiology,Affiliated Hospital of Nantong University,Nantong Jiangsu 226001,China)
出处
《昆明医科大学学报》
CAS
2023年第9期126-135,共10页
Journal of Kunming Medical University
基金
南通市科技局基础科学研究公众健康基金资助项目(JC2021196)。
